Literature DB >> 24713741

Low ER+ breast cancer: Is this a distinct group?

Nika C Gloyeske1, David J Dabbs, Rohit Bhargava.   

Abstract

OBJECTIVES: Estrogen receptor (ER) level can be semiquantified by immunohistochemistry (IHC) using the H-score. The score, given as the sum of the percent staining multiplied by the intensity level, ranges from 0 to 300.
METHODS: Forty-nine ER+/HER2- invasive tumors with low ER expression (H-scores of 1-100, representing approximately 5% of all tumors) were studied for various morphologic parameters, progesterone receptor (PR), and Ki-67 IHC.
RESULTS: Eighteen of 49 patients received neoadjuvant chemotherapy. The morphologic analysis showed that these tumors are often grade 3 and frequently demonstrate a sheet-like growth pattern, an intratumoral lymphocytic inflammatory infiltrate, and necrosis. Eighty percent of tumors showed a Ki-67 proliferation index of more than 50%, and 94% were PR-. Of the 18 patients who received neoadjuvant chemotherapy, six (33%) achieved pathologic complete response.
CONCLUSIONS: The low ER+/HER2- cases have morphologic features and a response to the chemotherapy rate that are more similar to triple-negative tumors than the usual type of ER+ tumors.

Entities:  

Keywords:  Low ER+/HER2-; Morphology; Response to neoadjuvant chemotherapy

Mesh:

Substances:

Year:  2014        PMID: 24713741     DOI: 10.1309/AJCP34CYSATWFDPQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  IL-1 induces p62/SQSTM1 and autophagy in ERα+ /PR+ BCa cell lines concomitant with ERα and PR repression, conferring an ERα- /PR- BCa-like phenotype.

Authors:  Afshan Fathima Nawas; Ragini Mistry; Shrinath Narayanan; Shayna Elizabeth Thomas-Jardin; Janani Ramachandran; Jananisree Ravichandran; Ebin Neduvelil; Krisha Luangpanh; Nikki Ayanna Delk
Journal:  J Cell Biochem       Date:  2018-10-15       Impact factor: 4.429

Review 2.  Updates on breast biomarkers.

Authors:  Saleh Najjar; Kimberly H Allison
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.535

3.  Prognostic and predictive parameters in breast pathology: a pathologist's primer.

Authors:  Kimberly H Allison
Journal:  Mod Pathol       Date:  2020-11-05       Impact factor: 7.842

4.  Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.

Authors:  Jean-Christophe Tille; André F Vieira; Caroline Saint-Martin; Lounes Djerroudi; Laëtitia Furhmann; Francois-Clement Bidard; Youlia Kirova; Anne Tardivon; Fabien Reyal; Matthieu Carton; Anne Vincent-Salomon
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

5.  Divergent and convergent evolution in metastases suggest treatment strategies based on specific metastatic sites.

Authors:  Jessica J Cunningham; Joel S Brown; Thomas L Vincent; Robert A Gatenby
Journal:  Evol Med Public Health       Date:  2015-03-20

6.  Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.

Authors:  Dovile Zilenaite; Allan Rasmusson; Renaldas Augulis; Justinas Besusparis; Aida Laurinaviciene; Benoit Plancoulaine; Valerijus Ostapenko; Arvydas Laurinavicius
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

7.  Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China.

Authors:  Yuqin Ding; Kaijing Ding; Kun Yu; Dehong Zou; Hongjian Yang; Xiangming He; Wenju Mo; Xingfei Yu; Xiaowen Ding
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

8.  PARP inhibition in breast cancer: progress made and future hopes.

Authors:  Nadine Tung; Judy E Garber
Journal:  NPJ Breast Cancer       Date:  2022-04-08

9.  Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry.

Authors:  Stefan Stefanovic; Ralph Wirtz; Thomas M Deutsch; Andreas Hartkopf; Peter Sinn; Zsuzsanna Varga; Bettina Sobottka; Lakis Sotiris; Florin-Andrei Taran; Christoph Domschke; Andre Hennigs; Sara Y Brucker; Christof Sohn; Florian Schuetz; Andreas Schneeweiss; Markus Wallwiener
Journal:  Oncotarget       Date:  2017-05-19

10.  Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study.

Authors:  Richard Sleightholm; Beth K Neilsen; Safwan Elkhatib; Laura Flores; Saihari Dukkipati; Runze Zhao; Songita Choudhury; Bret Gardner; Joey Carmichael; Lynette Smith; Nathan Bennion; Andrew Wahl; Michael Baine
Journal:  J Clin Med Res       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.